QR kód

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis

Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), a CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man with multiple c...

Celý popis

Uloženo v:
Hlavní autoři: Aimee Schad, Abhinandan R Pakanati, Susan Woelich, Abhishek Chilkulwar
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2023-09-01
Edice:Current Problems in Cancer: Case Reports
Témata:
Classical Hodgkin Lymphoma
Brentuximab vedotin
ESRD
Hemodialysis
Pharmacology
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2666621923000339
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky